Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target

Clinical Cancer Research

Volumn 16, Issue 3, 2010, Pages 814-824

  Jia, Lijun ^a   Yang, Jie ^a   Hao, Xinbao ^a   Zheng, Min ^a   He, Hongbin ^a   Xiong, Xiufang ^a   Xu, Liang ^a   Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; MESSENGER RNA; PROTEIN NOXA; PROTEIN SAG; RING FINGER PROTEIN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTITUMOR GENE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LUNG CANCER; MOLECULAR CLONING; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OXIDATION REDUCTION REACTION; PANCREAS CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; RING FINGER MOTIF; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; GENE SILENCING; HUMANS; MALE; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION-SENSITIZING AGENTS; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 76049102305     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1592     Document Type: Article

References (40)

1. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006;5: 596-613.
2. Orlowski RZ. Proteasome inhibitors in cancer therapy. Methods Mol Biol 2005;301:339-50.
3. Nikiforov MA, Riblett M, Tang WH, et al. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 2007;104:19488-93.
4. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006;6:369-81.
5. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6:9-20.
6. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008;8:438-49.
7. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008;8:83-93.
8. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321: 1499-502.
9. 2-M arrest, apoptosis, and senescence. Cancer Res 2009;69:4974-82.
10. Duan H, Wang Y, Aviram M, et al. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol Cell Biol 1999;19:3145-55.
11. Sun Y, Tan M, Duan H, Swaroop M. SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. Antioxid Redox Signal 2001;3:635-50.
12. Swaroop M, Bian J, Aviram M, et al. Expression, purification, and biochemical characterization of SAG, a RING finger redox sensitive protein. Free Radic Biol Med 1999;27:193-202.
13. Sun Y. Alteration of SAG mRNA in human cancer cell lines: requirement for the RING finger domain for apoptosis protection. Carcinogenesis 1999;20:1899-903.
14. Yang ES, Park JW. Regulation of nitric oxide-induced apoptosis by sensitive to apoptosis gene protein. Free Radic Res 2006;40:279-84.
15. Chanalaris A, Sun Y, Latchman DS, Stephanou A. SAG attenuates apoptotic cell death caused by simulated ischaemia/reoxygenation in rat cardiomyocytes. J Mol Cell Cardiol 2003;35:257-64.
16. Lee SJ, Yang ES, Kim SY, Shin SW, Park JW. Regulation of heat shock-induced apoptosis by sensitive to apoptosis gene protein. Free Radic Biol Med 2008;45:167-76.
17. Kim SY, Kim MY, Mo JS, Park JW, Park HS. SAG protects human neuroblastoma SH-SY5Y cells against 1-methyl-4-phenylpyridinium ion (MPP+)-induced cytotoxicity via the downregulation of ROS generation and JNK signaling. Neurosci Lett 2007;413:132-6.
18. Gu Q, Bowden TG, Normolle D, Sun Y. SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage dependent targeting of c-Jun/AP1 and IκB/NF-κB. J Cell Biol 2007;178:1009-23.
19. Sasaki H, Yukiue H, Kobayashi Y, et al. Expression of the sensitive to apoptosis gene, SAG, as a prognostic marker in nonsmall cell lung cancer. Int J Cancer 2001;95:375-7.
20. Zheng M, Morgan-Lappe SE, Yang J, et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 2008;68:7570-8.
21. Gu Q, Tan M, Sun Y. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol- 13-acetate-induced neoplastic transformation. Cancer Res 2007;67:3616-25.
22. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL-and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005;24: 7381-8.
23. Khanbolooki S, Nawrocki ST, Arumugam T, et al. Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006;5:2251-60.
24. Huang Y, Duan H, Sun Y. Elevated expression of SAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but its antisense transfection inhibits tumor cell growth. Mol Carcinog 2001;30:62-70.
25. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004;14:259-66.
26. Wang CC, Liao YP, Mischel PS, Iwamoto KS, Cacalano NA, McBride WH. HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res 2006;66:6756-62.
27. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2003;2:623-9.
28. Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006;8:645-54.
29. Yang GY, Pang L, Ge HL, et al. Attenuation of ischemia-induced mouse brain injury by SAG, a redox-inducible antioxidant protein. J Cereb Blood Flow Metab 2001;21:722-33.
30. Fulda S. Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 2007;7:1255-64.
31. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000;407:810-6.
32. Fernandez Y, Verhaegen M, Miller TP, et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005;65:6294-304.
33. Ploner C, Rainer J, Lobenwein S, Geley S, Kofler R. Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells. Apoptosis 2009;14:821-8.
34. Yen HC, Elledge SJ. Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science 2008;322:923-9.
35. Yen HC, Xu Q, Chou DM, Zhao Z, Elledge SJ. Global protein stability profiling in mammalian cells. Science 2008;322:918-23.
36. Short SC. External beam and conformal radiotherapy in the management of gliomas. Acta Neurochir Suppl 2003;88:37-43.
37. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005;172:523-9.
38. He H, Gu Q, Zheng M, Normolle D, Sun Y. SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27. Carcinogenesis 2008;29:858-65.
39. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008;19:125-32.
40. Howard KA, Kjems J. Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opin Biol Ther 2007;7: 1811-22.